Genomic Characteristics and Clonal Evolution of EGFR-mutated Lung Adenocarcinoma-Transformed Squamous Carcinoma after EGFR-TKIs Treatment

被引：0
|
作者：
Kang, J. [1 ]
Yang, X. -N. [1 ]
Yan, L. -X. [2 ]
Yan, L. [3 ]
Yang, J. -J. [1 ]
机构：
[1] Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[3] Shanghai Tongshu Biotech Co Ltd, Shang Hai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
epidermal growth factor receptor; lung adenocarcinoma to; squamous cell carcinoma tra; drug resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-10
引用
收藏
页码：S335 / S335
页数：1
相关论文
共 50 条
  • [31] Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
    Lee, S. H.
    Park, M. J.
    Chang, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S572 - S572
  • [32] Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer.
    Wang, Ran Lin
    Li, Tao
    Lv, Jiahua
    Sun, Chang
    Shi, Qiuling
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs
    Lee, Seung Hyeun
    Park, Myung Jae
    Chang, Boksoon
    CANCER RESEARCH, 2019, 79 (13)
  • [34] EGFR-TKIs Combined with Allogeneic CD8+NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer
    Daungsupawong, Hinpetch
    Wiwanitkit, Viroj
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [35] Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
    Jeon, W.
    Lim, B.
    Han, S.
    Kwack, W.
    Chang, B.
    Choi, H.
    Kim, Y.
    Choi, C.
    Park, M.
    Yoo, J.
    Lee, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [36] Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer
    Shinohara, Shinji
    Ichiki, Yoshinobu
    Fukuichi, Yukiko
    Honda, Yohei
    Kanoyama, Masatoshi
    Taira, Akihiro
    Nabe, Yusuke
    Kuwata, Taiji
    Takenaka, Masaru
    Oka, Soichi
    Chikaishi, Yasuhiro
    Hirai, Ayako
    Imanishi, Naoko
    Kuroda, Koji
    Yoneda, Kazue
    Noguchi, Hirotsugu
    Tanaka, Fumihiro
    JOURNAL OF THORACIC DISEASE, 2018, 10 (07) : E526 - E531
  • [37] Cell-free DNA from EGFR-mutated lung cancer cells treated with EGFR-TKIs engages in innate immune signaling pathways
    Shiiya, Akihiko
    Noguchi, Takuro
    Ariga, Shin
    Ohhara, Yoshihito
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Akita, Hirotoshi
    CANCER SCIENCE, 2022, 113 : 835 - 835
  • [38] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study
    Hu, Chunhong
    Wu, Sixuan
    Deng, Renfang
    Wu, Yuanqiang
    Pan, Yue
    Shu, Long
    Wu, Fang
    CANCER MEDICINE, 2023, 12 (01): : 266 - 273
  • [39] Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma
    Tambo, Yuichi
    Sone, Takashi
    Kasahara, Kazuo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : E199 - E200
  • [40] Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor
    Kuiper, Justine L.
    Ronden, Merle I.
    Becker, Annemarie
    Heideman, Danielle A. M.
    van Hengel, Peter
    Ylstra, Bauke
    Thunnissen, Erik
    Smit, Egbert F.
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (04) : 320 - 321
12345